HSBC Cuts Biogen Rating as MS Business Weakens
HSBC downgraded Biogen to Reduce, citing weakness in its multiple sclerosis business, margin pressure, and limited near-term earnings growth.
HSBC downgraded Biogen to Reduce, citing weakness in its multiple sclerosis business, margin pressure, and limited near-term earnings growth.
Novo Nordisk shares tumbled 10% after Ozempic failed to slow Alzheimer's progression in clinical trials, marking another setback for the struggling Danish drugmaker against rival Eli Lilly.
The US approved Leqembi IQLIK, an at-home self-injected Alzheimer's drug by Eisai & Biogen, for patients completing 18 months of IV infusions. Costing $19,500/year, it aims to boost access, convenience, and sales, despite concerns over side effects like brain swelling and bleeding.